JPX · 4596.T
Kubota Pharmaceutical Holdings Co., Ltd.
¥57-¥1 (-1.72%)
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
Loading market information…
JPX · 4570.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Immuno-Biological Laboratories Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 73.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Immuno-Biological Laboratories Co., Ltd.’s forward annual dividend is ¥6 per share, paid annual. The forward yield is 0.58% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Immuno-Biological Laboratories Co., Ltd.’s next earnings report is currently expected on Nov 11, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Immuno-Biological Laboratories Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:01 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥57-¥1 (-1.72%)
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
¥363-¥6 (-1.63%)
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
¥212-¥2 (-0.93%)
Soiken Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.77% below the high.
¥1,181-¥22 (-1.83%)
Living Platform,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
¥64-¥2 (-3.03%)
Ribomic Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
¥59-¥2 (-3.28%)
D. Western Therapeutics Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.85% below the high.
¥591+¥4 (+0.68%)
Human Metabolome Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.85% below the high.
¥142+¥2 (+1.43%)
Perseus Proteomics Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.24% below the high.
